Introduction
Moyamoya disease (MMD) is a rare cerebrovascular disorder characterised by gradual narrowing or obstruction of the internal carotid arteries (ICA).1 This pathophysiological process gives rise to the formation of fragile collateral vessels at the base of the brain, consequently elevating susceptibility to ischaemic and haemorrhagic events, which are the cardinal clinical manifestations of this condition.2 3 The cause of MMD remains unknown despite collaborative investigations. Nevertheless, the nature of revascularisation interventions to improve cerebral blood flow dynamics and prevent cerebrovascular events is crucial. Revascularisation, which comprises direct and indirect modalities, has become the mainstay therapeutic intervention for MMD. Its objective is to restore adequate cerebral perfusion and mitigate the risk of a subsequent stroke.4 5
Nonetheless, the judicious timing of surgical intervention remains a challenge in managing MMD.6 This challenge arises from the complex equilibrium among the natural progression of the disease, evolution of collateral vascular pathways and optimal window for surgical intervention.7 Determining the precise junction at which revascularisation confers optimal outcomes is challenging. Studies show that delayed surgical intervention may escalate vulnerability to cerebral infarction, whereas early initiation may prevent the maturation of collateral vessels, potentially compromising the efficacy of revascularisation.8
The magnitude and efficacy of collateralisation for revascularisation in MMD have been subjects of intensive investigation. The complex interplay among the ICAs, their associated collateral networks and the external carotid artery (ECA) system contributes to the complex and multifaceted nature of revascularisation outcomes.9 10 Previous studies primarily relied on qualitative assessments of angiographic imagery, restricting comprehensive and quantitative evaluations of postoperative collateralisation.11 12
This investigation quantitatively evaluated the collateralisation of the ECA and the intracranial arterial residual volumes (ARV) after cerebral revascularisation in patients with MMD. Our research aimed to introduce a novel perspective on this subject. We further aimed to explain the determinants influencing the collateralisation of the ECA in patients with MMD after cerebral revascularisation. This integrated approach can help bridge the gap between disease progression, the collateralisation of the ECA and optimal timing for surgical intervention. Thus, it provides valuable insights that can effectively guide clinical practices, improving patient outcomes.